Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 11, 2026 08:30 ET | Source: Ascend Learning, Inc.

ATI Engage® Honored for Advancing Digital Learning in Nursing Education

ATI Engage® Series, a product by ATI Nursing Education, is the winner of the Digital Learning Innovation Award in the 8th annual EdTech Breakthrough Awards
June 11, 2026 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment Updated Phase 1a data further supports a median...
June 10, 2026 07:30 ET | Source: Cervomed

CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies

Additional funding will extend anticipated runway into second quarter of 2027 Strategic priority is to establish a partnership to advance neflamapimod into Phase 3 in dementia with Lewy bodies ...
June 08, 2026 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses

KT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and clinically active therapies in multiple preclinical lupus models KT-579 Phase 1 healthy volunteer...
June 08, 2026 06:00 ET | Source: Shattuck Labs, Inc.

Shattuck Labs Announces Phase 1 Results for SL-325

Potentially best-in-mechanism immunogenicity profile, with only 3.7% of participants developing antidrug antibodies Complete blockade of TL1A binding to DR3 for over 3 months expected at doses of 1...
June 03, 2026 07:30 ET | Source: Dyne Therapeutics, Inc.

Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)

- Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 - WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a...
June 02, 2026 07:00 ET | Source: Entrada Therapeutics, Inc.

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study

An independent safety Data Monitoring Committee recommends the initiation of Cohort 2 in Entrada Therapeutics’ ELEVATE-45-201 study.
June 02, 2026 03:35 ET | Source: Mordor Intelligence

Black Mass Recycling Market Growing at CAGR of 18.91% by 2031, Fueled by Government Recycling Policies & Clean Energy Initiatives | Says Mordor Intelligence

Hyderabad, India, June 02, 2026 (GLOBE NEWSWIRE) -- According to Mordor Intelligence, the global black mass recycling market size is experiencing strong growth, with its value expected to rise...
June 01, 2026 07:00 ET | Source: Jade Biosciences

Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy

~70% IgA reductions sustained at 12 weeks after a single dose of JADE101>70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeksIgA-lowering...
May 27, 2026 18:06 ET | Source: Cerrado Gold Inc

Cerrado Gold Announces First Quarter 2026 Financial Results

Cerrado Gold releases Q1 2026 Financial Results